Róbert Wessman became the Executive Chairman of Alvogen in July 2009 and is now Chairman & CEO of the group. Since founding the business 6 years ago, Róbert has grown Alvogen from a small US business into a global pharmaceutical with commercial operations in 35 countries and with 2,500 employees.

Under his leadership, Alvogen has set a clear goal to become a top five global generics player, and is making strong progress towards that ambition. Wessman’s vision to create an organization which is able to respond to the needs of its customers has led to the development of a balanced yet specialized portfolio consisting of 500 marketed products, as well as a deep pipeline of high-value products in development.

Róbert is known for his clear focus and his ability to successfully combine operational efficiency and external growth through strategic acquisitions. Wessman has grown Alvogen’s revenue by an impressive 67% CAGR over the past six years, or by 59% on an organic basis. He has also overseen a number of strategic acquisitions and partnerships during that time, particularly to strengthen the company’s growth platforms in the APAC and CEE regions.

A business graduate and former lecturer at the University of Iceland, Wessman began his career at the Icelandic shipping company Samskip where he quickly advanced to the post of CEO in Germany. In 1999, he became President and CEO of Delta in 1999, which later formed Actavis. Wessman was CEO of Actavis Group, which became one of the largest generic pharmaceutical companies in the world for nine years.

His achievements have made him the subject of a Harvard Business School Case Study published in May 2008, titled “Róbert Wessman and the Actavis Winning Formula”.

Róbert Wessman

Petar Vazharov is the Executive Vice President of APAC, responsible for executing the growth strategy across the APAC market. Petar joined Alvogen Group in 2009, after 9 years with the generic pharmaceutical company Actavis Group in various roles, and has demonstrated his ability to lead the CEE business by delivering 75% CAGR of EBITDA during 2013 to 2015.

Petar graduated with a medical doctor’s degree from Sofia University of Medicine in 1999 and has an MBA degree from University of Sofia “Kliment Ohridski” in October 2007.

Petar Vazharov

Thor Kristjansson is EVP of Corporate Finance and M&A of Alvogen’s global operation. He has over 25 years experience through various positions, specializing in finance, project management and general management.

Thor served as Deputy CEO of Actavis from 2001 till 2004. His key focus was generating external growth through M&A. Prior to joining Alvogen in 2010, Thor worked for several private equity firms specializing in different sectors and he also served as BOD members of several international companies in multiple regions from 2005 prior to joining Alvogen.

Thor Kristjansson

Joel Morales became Chief Financial Officer at Alvogen in September 2017. Before joining Alvogen, he worked for Endo International plc, where he was SVP of the Generics Business Segment and Global Finance Operations. He was also responsible for a number of enterprise-wide strategic initiatives in direct support of the CEO and Executive Leadership Team. Prior to joining Endo, he worked for Merck & Co. and Schering-Plough, where he spent 10 years in various leadership roles, including the Corporate Strategy Office, Business Development and International Finance.

Joel began his career with KPMG LLP, and is a licensed certified public accountant in the State of New Jersey. He obtained his Bachelor of Science degree in accounting from Rutgers University.

Joel Morales

Ms. Amporn Charoensomsak joined Lotus’ Board of Directors on April 22nd after Innobic (Asia) becomes Lotus’ strategic partner and shareholder in the same month. She currently is Managing Director at Innobic (Asia) responsible for PTT Group’s life science business in Thailand and also a member of Medical Governance Foundation and Pharmaceutical Association of Thailand under Royal Patronage.

Ms. Amporn has more than 30 years experience in pharmaceutical industry. Before joining Innobic (Asia), she was Country Manager of Abbott Laboratories Ltd (Thailand) and worked at other big pharma, including Pfizer and Novartis Thailand. Ms. Amporn obtained her MBA degree from Thammasat University and Bachelor of Pharmaceutical Science from Chulalongkorn University.

Amporn Charoensomsak

Mr. Hirofumi Imai was the CEO of Fuji Pharma, a company based in Japan, for 18 years since 1998. Under his leadership, the company established itself as a market leader in the women's health market as well as in the diagnostic imaging market, and its EBITDA and market capitalization increased seven times and ten times, respectively. In 2012, the company got listed on the first section of the Tokyo Stock Exchange and also played a pivotal role in concluding the strategic partnership with Lotus Pharmaceuticals in 2019. Mr. Imai currently serves as the Chairman of Fuji Pharma.

Hirofumi Imai

Mr. Palsson joined Lotus’s Board of Directors on April 23rd, 2015. He currently serves as independent non-executive Board member and Business Consultant in various different sectors, including financial, pharmaceuticals, telecommunications and non-profits organizations across the world. Mr. Palsson is also the Chairman of Lotus’s Audit Committee.

Mr. Palsson was EVP and CFO of a leading medical device company, listed on NASDAQ OMX Copenhagen, from 2001 to 2013. He gained comprehensive experience in leading Accounting, Planning, Investor Relations, Financing, Corporate M&A, Human Resources and Business Information Services there. Prior to that, Mr. Palsson was a partner and a Board member at Deloitte & Touche in Iceland where he practiced as a State Authorized Public Accountant. 

Hjiorleifur Palsson

Mr. Ku is Attorney at Law in Cheng & Ku Law Firm and serves as independent director of Lotus. He has 15 years experience as a professional lawyer in various law firms in Taiwan and in-house counsel for Taiwan corporations.

Mr. Ku passed his bar exam in 1999 and patent agent certification in Taiwan in 2001. He is a member of Taipei Bar, Keelung Bar, Taoyuan Bar and Taichung Bar Associations in Taiwan.

Benjamin Ku

Mr. Lin joined Lotus’s Board of Directors on June 27th, 2016. He is currently a Partner with the CID Group, one of the fastest growing venture capital and private equity firms in Asia.

Previously, Han-Fei was the Chief Finance Officer of MStar Semiconductor, Inc., a leading IC design firm with a broad range of technologies serving the world’s top consumer electronics and communications companies.  During his tenure, he successfully brought the company public with introducing Temasek and GIC as anchor investors, and the deal is still one of the largest IPO in Taiwan’s history.  He also played a critical role in negotiating and executing MStar’s merger with Mediatek, which created one of the largest fabless IC design houses in the world.

Prior to CID and MStar, Han-Fei served as Director of Investments at Foxconn, and founded and served as CEO of Asia Bioinnovations, a biotech firm located in the Bay Area of California.

Han-Fei Lin

Lotus’s Board of Directors consists of nine distinguished members with an exceptional knowledge and experience in the related fields. Three out of nine directors are independent directors and perform their duties in accordance with the Company’s Articles of Incorporation and relevant bylaws to protect the interests of all shareholders.

The Board of Directors supervises the Company’s operation and compliance with relevant laws and regulations as well as provides guidance to the Company’s management team to maximize shareholders' value in the long run.  The Board of Directors is also responsible for evaluating the management team’s performance and ensuring the team running the business operations in a disciplined and prudent way.